Rapiscan

RSS

regadenoson

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Rapiscan. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rapiscan.

This EPAR was last updated on 30/06/2022

Authorisation details

Product details
Name
Rapiscan
Agency product number
EMEA/H/C/001176
Active substance
regadenoson
International non-proprietary name (INN) or common name
regadenoson
Therapeutic area (MeSH)
Myocardial Perfusion Imaging
Anatomical therapeutic chemical (ATC) code
C01EB21
Publication details
Marketing-authorisation holder
GE Healthcare AS 
Revision
14
Date of issue of marketing authorisation valid throughout the European Union
06/09/2010
Contact address
GE Healthcare AS
Nycoveien 1
NO-0485 Oslo
Norway

Product information

13/12/2021 Rapiscan - EMEA/H/C/001176 - II/0038

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Cardiac therapy

Therapeutic indication

This medicinal product is for diagnostic use only.

Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
Average
5 ratings
1 rating
1 rating